Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety.
Res Pract Thromb Haemost
; 5(6): e12576, 2021 Aug.
Article
en En
| MEDLINE
| ID: mdl-34430790
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Res Pract Thromb Haemost
Año:
2021
Tipo del documento:
Article